A pharmacokinetic study of INP107 for pivotal dose selection
Latest Information Update: 22 Sep 2022
Price :
$35 *
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Impel Pharmaceuticals
- 05 Oct 2021 New trial record
- 29 Sep 2021 According to an Impel NeuroPharma media release, company plans to initiate this study in 2022.